Kadence Bio Pioneers Innovative Therapies for Sexual and Mental Health
Kadence Bio (formerly Kanna Health) is a clinical-stage drug development company pioneering new treatments for sexual health. Their lead asset, KH-001, is being developed as the first FDA-approved treatment for premature ejaculation. The company recently completed a Phase I clinical trial and is planning to initiate Phase II trials next year.